DPP4 and susceptibility to pneumonia measurement: In the present study, we compared the risk of respiratory infection (a composite endpoint event of acute upper respiratory infections, influenza, pneumonia and other acute lower respiratory infections) associated with DPP-4 inhibitor + insulin versus metformin + insulin combination therapy in progressed T2DM patients.